Waldencast (WALD) announced that the U.S. FDA has approved Obagi saypha MagIQ injectable hyaluronic acid gel, the first product in the Obagi saypha collection under the Obagi Medical brand. This approval marks Waldencast’s entry into the U.S. HA dermal filler market through Obagi Medical and reinforces the company’s ambition to become a multi-product innovator in aesthetics, doubling Obagi Medical’s total addressable market to approximately $4.2B by 2029.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WALD:
- Waldencast Reports Strategic Growth and New Acquisitions
- Waldencast’s Strategic Positioning and Growth Potential: A Buy Rating Amidst Strategic Review and Financial Restructuring
- Waldencast price target lowered to $3 from $4 at Telsey Advisory
- Waldencast price target lowered to $2 from $2.40 at TD Cowen
- Waldencast Reports Strong H1 2025 Growth and Strategic Initiatives